請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73239完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李宗徽(Tzong-Huei Lee) | |
| dc.contributor.author | Tsai-Yen Shih | en |
| dc.contributor.author | 石采艷 | zh_TW |
| dc.date.accessioned | 2021-06-17T07:24:05Z | - |
| dc.date.available | 2019-07-15 | |
| dc.date.copyright | 2019-07-15 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2019-07-02 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73239 | - |
| dc.description.abstract | 本研究利用抑制金黃色葡萄球菌 (Staphylococcus aureus) 和新型隱球菌(Cryptococcus neoformans) 的活性為篩選平台，針對從基隆八斗子所採集的海藻分離出之343株藻源真菌株，進行了初步的抑菌活性測試。結果發現由石蓴 (Ulva lactuca) 單離出之衍生真菌株Aspergillus sp. NTU967的PDY (Peptone, Dextrose, Yeast Extract) 發酵培養液，以及使用發芽糙米培養的萃取液，皆具有明顯的抑菌效果。接著以PDY液態培養基與發芽糙米進行大量培養，針對其發酵液所含之代謝產物進行分析、分離與純化，計獲得13個化合物，藉由各種光譜分析決定其化合物結構。其中有8個為新化合物，分別為aspergilsmins A − H (1 − 7和13)，另外5個為已知化合物，分別為clavatol (8)、deoxytryptoquivaline (9)、tryptoquivaline (10)、quinadoline B (11) 和 (4-oxo-5,6-dihydro-4H-pyran-3-yl)-acetic acid (12)。後續在各種活性平台的評估上，得知aspergilsmins E (5) 和F (6) 具最佳的抑菌活性，對於金黃色葡萄球菌 (Staphylococcus aureus) 的最小抑菌濃度 (MIC) 皆為32 μg/ml；在抑制人類前列腺癌細胞 (Prostate cancer cells; PC-3) 和人類肝癌細胞 (hepatocellular carcinoma cells; SK-Hep-1) 上，aspergilsmin C (3) 具有顯著的效果，其半抑制濃度 (IC50) 分別為7.3 ± 0.3和 2.7 ± 0.2 μM；所有化合物對於小鼠神經膠質BV-2細胞皆不具顯著抑制NO產生的活性。對於化合物3的抗癌細胞毒性詳細作用機制，仍有待進一步實驗證實。 | zh_TW |
| dc.description.abstract | Among the mairne microorganisms, marine-derived fungi are able to produce lots of secondary metabolites with highly structural diversity. The discovery of new natural products from marine-derived fungi has increased dramatically over the last few decades, and some of them revealed great potentials for drug developments. In our preliminary screening, the bioactivities of 343 fungal strains, isolated from marine macroalgae collected from northeast coast of Taiwan, were tested intensively. Of these, the ethyl acetate extract of the fermented broth of Aspergillus sp. NTU967, isolated from a marine green alga Ulva lactuca, was found to exhibit significant antimicrobial activities against Staphylococcus aureus and Cryptococcus neoformans. Therefore, bioassay-guided separations of the active principles from liquid- or solid-state fermentations of Aspergillus sp. NTU967 were carried out, and which have led to isolation and purification of compounds 1 – 13 . Their structures were elucidated by spectroscopic analysis to be eight new aspergilsmins A − H (1 − 7 and 13), together with five previously reported clavatol (8), deoxytryptoquivaline (9), tryptoquivaline (10), quinadoline B (11) and (4-oxo-5,6-dihydro-4H-pyran-3-yl)-acetic acid (12). Aspergilsmins E (5) and F (6) exhibited significant growth inhibition against Staphylococcus aureus with the minimum inhibitory concentration (MIC) of 32 μg/ml. Aspergilsmin C (3) showed cytotoxic activity against prostate cancer cells (PC-3) and hepatocellular carcinoma cells (SK-Hep-1), and the half inhibitory concentrations (IC50) were 7.3 ± 0.3 and 2.7 ± 0.2 μM, respectively. The detailed mechanism of compound 3 against cancer cells remains to be confirmed by further experiments. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T07:24:05Z (GMT). No. of bitstreams: 1 ntu-107-R05B45006-1.pdf: 7890469 bytes, checksum: 9db5b8ab9ab52afa2b37c4dd95600e68 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 致謝..........................I
中文摘要..........................II 英文摘要..........................III 目錄..........................VI 表目錄..........................X 圖目錄..........................XII 縮寫表..........................XVII 第一章 緒論與研究目的..........................1 1.1 緒論..........................1 1.2 研究目的..........................4 第二章 文獻回顧..........................5 2.1 真菌株之分類學與介紹..........................5 2.2 海洋源麴菌屬 (ASPERGILLUS SPP.) 真菌成分之文獻回顧.............5 第三章 實驗結果..........................36 3.1 真菌液態及固態醱酵萃取液分離流程..........................36 3.1.1 真菌株Aspergillus sp. NTU967 液態醱酵培養液分離流程..........36 3.1.2 真菌株Aspergillus sp. NTU967 固態醱酵萃取液分離流程..........38 3.2 天然物結構解析..........................40 3.2.1 Aspergilsmin A (1) 之結構解析..........................40 3.2.2 Aspergilsmin B (2) 之結構解析..........................47 3.2.3 Aspergilsmin C (3) 之結構解析..........................54 3.2.4 Aspergilsmin D (4) 之結構解析..........................62 3.2.5 Aspergilsmin E (5) 之結構解析..........................70 3.2.6 Aspergilsmin F (6) 之結構解析..........................78 3.2.7 Aspergilsmin G (7) 之結構解析..........................85 3.2.8 Clavatol (8) 之結構解析..........................93 3.2.9 Deoxytryptoquivalin (9) 與 Tryptoquivalin (10) 之結構解析...99 3.2.10 Quinadoline B (11) 之結構解析.........................111 3.2.11 (4-Oxo-5,6-dihydro-4H-pyran-3-yl)-acetic acid (12) 之結構解析...120 3.2.12 Aspergilsmin H (13) 之結構解析........................127 3.3 各成分之物理數據..........................136 3.4化合物活性平台測試..........................141 3.4.1 抑菌試驗結果..........................141 3.4.2 細胞毒性試驗..........................142 3.4.3一氧化氮抑制與細胞存活率之實驗結果..........................144 第四章 實驗部分..........................145 4.1儀器設備與試劑..........................145 4.1.1化合物之物理性質測定儀器..........................145 4.1.2管柱層析膠體..........................146 4.1.3試劑耗材與溶劑..........................146 4.1.4真菌培養基..........................146 4.1.5細菌培養基..........................147 4.2實驗材料..........................147 4.2.1真菌材料..........................147 4.2.2細菌材料..........................147 4.2.3菌種分子鑑定..........................147 4.2.4真菌菌株分離與篩選..........................149 4.3抗菌活性篩選..........................150 4.3.1檢測原理..........................150 4.3.2測試菌種..........................150 4.3.3實驗步驟..........................150 4.4真菌培養及成分分離..........................151 4.4.1 培養基配置..........................151 4.4.2真菌菌種保存..........................151 4.4.3真菌液態醱酵液萃取..........................152 4.4.4真菌液態醱酵液之成分分離與純化..........................152 4.4.5真菌固態醱酵液萃取..........................154 4.4.6真菌固態醱酵液之成分分離與純化..........................155 4.5 抗菌活性評估..........................156 4.5.1 活性平台菌株培養..........................156 4.5.2 最小抑制濃度試驗..........................157 4.6 抗癌活性評估..........................157 4.6.1原理與目的..........................157 4.6.2細胞培養..........................157 4.6.3 Sulforhodamine B (SRB) assay..........................158 4.7 抗發炎活性評估..........................158 4.7.1 細胞培養..........................159 4.7.2 Griess reagent assay..........................159 第五章 討論..........................160 第六章 參考文獻..........................162 | |
| dc.language.iso | zh-TW | |
| dc.subject | 金黃色葡萄球菌 | zh_TW |
| dc.subject | aspergilsmin | zh_TW |
| dc.subject | Aspergillus sp. | zh_TW |
| dc.subject | 藻源真菌 | zh_TW |
| dc.subject | 抗癌 | zh_TW |
| dc.subject | 抗菌 | zh_TW |
| dc.subject | 白色念珠菌 | zh_TW |
| dc.subject | cytotoxic activity. | en |
| dc.subject | Aspergillus sp. | en |
| dc.subject | Staphylococcus aureus | en |
| dc.subject | Cryptococcus neoformans | en |
| dc.subject | anti-microbial activity | en |
| dc.subject | aspergilsmin | en |
| dc.subject | marine-derived fungi | en |
| dc.title | 海洋綠藻源真菌株 Aspergillus sp. NTU967 之成分研究 | zh_TW |
| dc.title | Chemical Constituents from a Marine Green Alga-derived Fungus Aspergillus sp. NTU967 | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 宋秉鈞,蕭哲志,陳日榮,韓玉山 | |
| dc.subject.keyword | 藻源真菌,Aspergillus sp.,金黃色葡萄球菌,白色念珠菌,抗菌,抗癌,aspergilsmin, | zh_TW |
| dc.subject.keyword | marine-derived fungi,Aspergillus sp.,Staphylococcus aureus,Cryptococcus neoformans,anti-microbial activity,aspergilsmin,cytotoxic activity., | en |
| dc.relation.page | 176 | |
| dc.identifier.doi | 10.6342/NTU201801577 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-07-02 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 漁業科學研究所 | zh_TW |
| 顯示於系所單位： | 漁業科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-1.pdf 未授權公開取用 | 7.71 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。